|
|
Wasting Research
General Research
- Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com
- Rosiglitazone Linked to Benign Tumors in Man With Lipodystrophy (August 17, 2004)
A case report ties the use of rosiglitazone, an experimental treatment for lipodystrophy-related fat loss, to the development of lipomas in one HIV-infected person.
From aidsmap.com
- Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
- In HIV Patients With Lipoatrophy, Antioxidants Lead to Only Modest Improvement in LDL Cholesterol (August 15, 2003)
From aidsmap.com
- FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Current Research on the Mechanisms Causing Lipoatrophy and Potential Treatments (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Rosiglitazone May Be Effective in Increasing Body Fat in Patients With Fat Wasting (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Serostim Study Initiated (Spring 2001)
In CRIA Update, from AIDS Community Research Initiative of America
- Thalidomide Pharmacokinetics, Safety and Effect on HIV Viral Load and Immune Parameters (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Hormones and Body Composition (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Exercise and HIV Wasting: From the Laboratory to the Clinic (July 2000)
In Body Positive, from Body Positive
- The Use of Testosterone in AIDS Wasting Syndrome (May 3, 1999)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- The Changing Face of Malnutrition and HIV (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
- Treating HIV-Associated Weight Loss and Wasting (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
- Anabolic Steroids, Exercise and Wasting (April 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- The Effects of Oxandralone on Body Weight and Composition in Patients With HIV-Associated Weight Loss (July 2, 1998)
In The 12th International AIDS Conference, from The Body PRO
- HIV-Related Clinical Updates: Wasting/Endocrine Disorders (May 2, 1998)
In The 8th Clinical Care Options for HIV Symposium, from The Body PRO
- Diagnosis and Treatment of Endocrine Disorders in the HIV-Infected Patient (February 1998)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
- Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens (August 1997)
In TAGline, from Treatment Action Group
- Anabolic Steroid Boosts Weight (September 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Wasting Syndrome: Oral Oxandrolone Re-Released in U.S. (December 22, 1995)
In AIDS Treatment News, from AIDS Treatment News
|
|
